title: Dengue virus inactivation by minipool TnBP/Triton X-45 treatment of plasma and cryoprecipitate.
abstract: OBJECTIVE
  A minipool solvent/detergent (S/D; 1% TnBP/1% Triton X-45; 31°C) process was developed for viral inactivation of plasma and cryoprecipitate used for transfusion. The goal of this study was to determine the rate and extent of inactivation of dengue virus (DENV) during this process.
  
  
  METHODS
  DENV-1 was propagated using C6/36 mosquito cells to an infectivity titre close to 9 log and spiked (10% v/v) into individual plasma and cryoprecipitate samples from two distinct donors. Samples were taken right after spiking and during viral inactivation treatment by 1% TnBP-1% Triton X-45 at 31°C. DENV-1 infectivity was assessed on Vero E6 cells by a focus-forming assay (FFA). Culture medium and complement-inactivated plasma were used as experimental controls. Experiments were done in duplicate.
  
  
  RESULTS
  DENV-1 infectivity was 7·5 log in spiked plasma and 7·1 and 7·3 log in spiked cryoprecipitate. There was no loss of DENV-1 infectivity in the spiked materials, nor in the controls not subjected to S/D treatment. No infectivity was found in plasma and cryoprecipitate subjected to S/D treatment at the first time-point evaluated (10 min).
  
  
  CONCLUSIONS
  DENV-1 was strongly inactivated in plasma and cryoprecipitate, respectively, within 10 min of 1% TnBP/1% Triton X-45 treatment at 31°C. These data provide a reassurance of the safety of such S/D-treated plasma and cryoprecipitate with regard to the risk of transmission of all DENV serotypes and other flaviviruses.
authors: Human Protein Process Sciences, Lille, France.
authors: T
authors: T
authors: Burnouf
authors: M-L
authors: ML
authors: Chou
authors: L-H
authors: LH
authors: Cheng
authors: Z-R
authors: ZR
authors: Li
authors: Y-W
authors: YW
authors: Wu
authors: M
authors: M
authors: El-Ekiaby
authors: K-H
authors: KH
authors: Tsai
mesh_terms: D000818:Animals; D001793:Blood Preservation; D058731:Blood Safety; D001803:Blood Transfusion; D002522:Chlorocebus aethiops; D003165:Complement System Proteins; D009033:Culicidae; D003715:Dengue / Q000517:prevention & control; D003716:Dengue Virus / Q000187:drug effects*; D003902:Detergents; D005169:Factor VIII / Q000737:chemistry; D005340:Fibrinogen / Q000737:chemistry; D006801:Humans; D017830:Octoxynol / Q000494:pharmacology*; D010755:Organophosphates / Q000494:pharmacology*; D010949:Plasma / Q000187:drug effects*; D012997:Solvents / Q000737:chemistry; D013997:Time Factors; D014709:Vero Cells; D038301:Virus Inactivation
chemical_list: D003902:Detergents; D010755:Organophosphates; D012997:Solvents; C026912:cryoprecipitate coagulum; D005169:Factor VIII; D005340:Fibrinogen; D017830:Octoxynol; D003165:Complement System Proteins; C009524:tributyl phosphate